

Johnson & Johnson Innovative Medicine Pipeline

Key Events in 2026*

POTENTIAL APPROVALS US/EU		PLANNED SUBMISSIONS US/EU		POTENTIAL CLINICAL DATA PRESENTATIONS ¹			
				Phase III		Phase I/II	
US TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)		US nipocalimab Warm Autoimmune Hemolytic Anemia (ENERGY)	US ERLEADA (apalutamide) EU Localized Prostate Cancer (ATLAS)	icotrokinra Psoriasis (ICONIC-ADVANCE 1&2 Update)	ERLEADA (apalutamide) Localized Prostate Cancer (ATLAS)	JNJ-4804 Co-antibody Therapy Ulcerative Colitis (DUET-UC)	
US icotrokinra EU Psoriasis (ICONIC)		US CAPLYTA (lumateperone) Bipolar Mania	US ERLEADA (apalutamide) EU High Risk Prostate Cancer (PROTEUS)	icotrokinra Psoriasis (ICONIC-ASCEND)	ERLEADA (apalutamide) High Risk Prostate Cancer (PROTEUS)	JNJ-4804 Co-antibody Therapy Crohn's Disease (DUET-CD)	
EU AKEEGA (niraparib/abiraterone) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)			US bleximinenib Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)	icotrokinra Psoriatic Arthritis (ICONIC-PsA)	TALVEY (talquetamab) Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)	JNJ-4804 Co-antibody Therapy Psoriatic Arthritis (AFFINITY)	
US DARZALEX (daratumumab) Frontline multiple myeloma transplant ineligible (CEPHEUS)			US TALVEY (talquetamab) EU Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)	icotrokinra Psoriasis (ICONIC-TOTAL Update)	TECVAYLI (teclistamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)	nipocalimab Systemic Lupus Erythematosus (JASMINE)	
US TECVAYLI (teclistamab) EU Multiple Myeloma 1-3PLs (MajesTEC-3)		US TECVAYLI (teclistamab) EU Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)	CAPLYTA (lumateperone) Bipolar Mania (ITI-007-452)	INLEXZO (gemcitabine intravesical delivery system) High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)	bleximinenib Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)		
		✓ EU TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3)	TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3)		JNJ-1887 sCD59 Geographic Atrophy (PARASOL)		
			INLEXZO (gemcitabine intravesical delivery system) EU High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)				

1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.

✓ = Achieved

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of January 21, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.